Pharming Group (PHAR) Competitors $10.04 -0.19 (-1.85%) Closing price 07/22/2025 03:56 PM EasternExtended Trading$10.02 -0.03 (-0.26%) As of 08:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAR vs. ALVO, MIRM, CPRX, GMTX, AMRX, NAMS, RARE, OGN, APLS, and IBRXShould you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Alvotech (ALVO), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), Gemini Therapeutics (GMTX), Amneal Pharmaceuticals (AMRX), NewAmsterdam Pharma (NAMS), Ultragenyx Pharmaceutical (RARE), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry. Pharming Group vs. Its Competitors Alvotech Mirum Pharmaceuticals Catalyst Pharmaceuticals Gemini Therapeutics Amneal Pharmaceuticals NewAmsterdam Pharma Ultragenyx Pharmaceutical Organon & Co. Apellis Pharmaceuticals ImmunityBio Pharming Group (NASDAQ:PHAR) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings. Do analysts prefer PHAR or ALVO? Pharming Group presently has a consensus price target of $30.00, indicating a potential upside of 198.78%. Alvotech has a consensus price target of $16.00, indicating a potential upside of 84.33%. Given Pharming Group's higher probable upside, research analysts plainly believe Pharming Group is more favorable than Alvotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharming Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Alvotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, PHAR or ALVO? Pharming Group has higher earnings, but lower revenue than Alvotech. Pharming Group is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharming Group$297.20M2.31-$11.84M-$0.20-50.21Alvotech$491.98M5.32-$231.86M$0.3723.46 Is PHAR or ALVO more profitable? Alvotech has a net margin of 16.42% compared to Pharming Group's net margin of -4.14%. Pharming Group's return on equity of -6.01% beat Alvotech's return on equity.Company Net Margins Return on Equity Return on Assets Pharming Group-4.14% -6.01% -3.23% Alvotech 16.42%-36.37%12.70% Do institutionals and insiders have more ownership in PHAR or ALVO? 0.0% of Pharming Group shares are held by institutional investors. 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, PHAR or ALVO? Pharming Group has a beta of 0.02, indicating that its share price is 98% less volatile than the S&P 500. Comparatively, Alvotech has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Does the media prefer PHAR or ALVO? In the previous week, Alvotech had 4 more articles in the media than Pharming Group. MarketBeat recorded 6 mentions for Alvotech and 2 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.07 beat Alvotech's score of 0.21 indicating that Pharming Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alvotech 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAlvotech beats Pharming Group on 8 of the 15 factors compared between the two stocks. Get Pharming Group News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAR vs. The Competition Export to ExcelMetricPharming GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$700.57M$2.92B$5.48B$9.44BDividend YieldN/A2.49%4.01%4.02%P/E Ratio-50.2020.5328.2919.90Price / Sales2.31265.95413.9185.75Price / Cash137.9441.6635.9658.29Price / Book3.097.808.345.67Net Income-$11.84M-$55.10M$3.24B$258.18M7 Day Performance0.91%4.62%3.14%2.81%1 Month Performance-4.23%17.99%10.99%13.53%1 Year Performance12.06%2.21%34.16%17.68% Pharming Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHARPharming Group2.386 of 5 stars$10.04-1.8%$30.00+198.8%+20.3%$700.57M$297.20M-50.20280Positive NewsALVOAlvotech3.396 of 5 stars$8.64+0.1%$16.00+85.2%-27.7%$2.60B$491.98M23.351,032MIRMMirum Pharmaceuticals4.099 of 5 stars$51.95+0.0%$65.50+26.1%+32.0%$2.57B$336.89M-32.27140Positive NewsCPRXCatalyst Pharmaceuticals4.9171 of 5 stars$21.01-0.1%$32.83+56.3%+22.9%$2.57B$491.73M13.3880Positive NewsGMTXGemini TherapeuticsN/A$57.770.0%N/A+29.2%$2.50BN/A-57.7730High Trading VolumeAMRXAmneal Pharmaceuticals2.8929 of 5 stars$7.91-0.8%$11.60+46.6%+6.8%$2.50B$2.83B-197.708,100NAMSNewAmsterdam Pharma3.617 of 5 stars$22.56+1.6%$41.30+83.1%+20.7%$2.49B$45.56M-12.004RAREUltragenyx Pharmaceutical4.3736 of 5 stars$26.39+0.3%$83.64+216.9%-40.5%$2.49B$560.23M-4.491,294Upcoming EarningsHigh Trading VolumeOGNOrganon & Co.4.855 of 5 stars$9.43-0.4%$18.00+91.0%-54.5%$2.46B$6.40B3.274,000APLSApellis Pharmaceuticals4.4142 of 5 stars$19.28-1.0%$40.00+107.5%-46.3%$2.45B$781.37M-10.77770Upcoming EarningsIBRXImmunityBio2.0878 of 5 stars$2.68-2.5%$12.25+357.1%-52.5%$2.43B$14.74M-4.62590 Related Companies and Tools Related Companies ALVO Competitors MIRM Competitors CPRX Competitors GMTX Competitors AMRX Competitors NAMS Competitors RARE Competitors OGN Competitors APLS Competitors IBRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHAR) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group N.V. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
